Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178 is registered in ClinicalTrials.gov with Tempus AI as lead sponsor.

NCT NCT07211178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07211178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Lead sponsor
Tempus AI
Phase
Observational
Overall status
Recruiting
Start date
October 27, 2025
Completion date
December 31, 2033
Enrollment
900 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early stage breast cancer, her2 + breast cancer, hr positive/her-2 negative breast cancer, tnbc - triple-negative breast cancer